CMS(00867),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

00867 CMS

Closed 03-02 16:08:34

14.160

-0.440

-3.01%

High14.520	Low14.000	Vol4.26M
Open14.300	D1 Closing14.600	Amplitude3.56%
Mkt Cap34.55B	Tradable Cap34.54B	Total Shares2.44B
T/O60.65M	T/O Rate0.17%	Tradable Shares2.44B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"00867","market":"HK","secType":"STK","nameCN":"CMS","latestPrice":14.16,"timestamp":1772438914003,"preClose":14.6,"halted":0,"volume":4260753,"delay":0,"changeRate":-0.03013698630136983,"floatShares":2439528512,"shares":2440000000,"eps":0.667298,"marketStatus":"Closed","change":-0.44,"latestTime":"03-02 16:08:34","open":14.3,"high":14.52,"low":14,"amount":60648162,"amplitude":0.035616,"askPrice":14.16,"askSize":15000,"bidPrice":14.14,"bidSize":21000,"shortable":3,"etf":0,"ttmEps":0.748149,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1772501400000},"marketStatusCode":5,"adr":0,"listingDate":1285603200000,"exchange":"SEHK","adjPreClose":14.6,"dividendRate":0.021031,"openAndCloseTimeList":[[1772415000000,1772424000000],[1772427600000,1772438400000]],"volumeRatio":1.158123,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00867/wiki","defaultTab":"wiki","newsList":[{"id":"1179446439","title":"CMS Receives Initial \"Buy\" Rating from Cinda Securities as Innovation-Driven Transformation Drives Long-Term Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1179446439","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179446439?lang=en_us&edition=fundamental","pubTime":"2026-02-25 10:12","pubTimestamp":1771985536,"startTime":"0","endTime":"0","summary":"Cinda Securities has issued a research report initiating coverage on CMS with a \"Buy\" rating. The firm forecasts the company's operating revenue for 2025-2027 to be RMB 8.216 billion, RMB 9.859...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015952.SGD","601059","IE00BVYPNQ40.USD","00867","BK0276","IE00BGHQDM52.EUR","IE00BMCWC346.EUR","SG9999004220.SGD","BK1191","IE00BYV24P56.USD","LU2488822045.USD","SG9999015945.SGD","SG9999015986.USD","SG9999015978.USD","BK1593","IE00BVYPNP33.GBP"],"gpt_icon":0},{"id":"2613712416","title":"BRIEF-CMS Says NDA For Additional Indication Atopic Dermatitis For Ruxolitinib Phosphate Cream Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=2613712416","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613712416?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:54","pubTimestamp":1771941265,"startTime":"0","endTime":"0","summary":"BRIEF-CMS Says NDA For Additional Indication Atopic Dermatitis For Ruxolitinib Phosphate Cream AcceptedFeb 24 (Reuters) - China Medical System Holdings Ltd 0867.HK:CMS (867.HK/8A8.SG): NDA FOR ADDITIO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK18H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015945.SGD","BK1593","IE00BYV24P56.USD","SG9999015978.USD","IE00BGHQDM52.EUR","SG9999015986.USD","LU2488822045.USD","SG9999015952.SGD","00867","BK1191","SG9999004220.SGD","IE00BVYPNQ40.USD","IE00BMCWC346.EUR","IE00BVYPNP33.GBP"],"gpt_icon":0},{"id":"2613971404","title":"CMS (867.HK/8a8.SG): Nda for Additional Indication Atopic Dermatitis (Ad) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2613971404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613971404?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:35","pubTimestamp":1771940141,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK18H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999015945.SGD","SG9999015986.USD","00867","IE00BMCWC346.EUR","BK1593","SG9999015952.SGD","IE00BYV24P56.USD","SG9999015978.USD","LU2488822045.USD","IE00BGHQDM52.EUR","IE00BVYPNQ40.USD","SG9999004220.SGD","IE00BVYPNP33.GBP","BK1191"],"gpt_icon":0},{"id":"2613712833","title":"China Medical System Holdings - Review Timeline Shortened From 200 Days to 130 Days","url":"https://stock-news.laohu8.com/highlight/detail?id=2613712833","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613712833?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:35","pubTimestamp":1771940141,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK18H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1593","SG9999015952.SGD","LU2488822045.USD","IE00BYV24P56.USD","SG9999015978.USD","IE00BVYPNQ40.USD","SG9999015986.USD","IE00BVYPNP33.GBP","00867","IE00BGHQDM52.EUR","SG9999004220.SGD","IE00BMCWC346.EUR","SG9999015945.SGD"],"gpt_icon":0},{"id":"1102276998","title":"CMS Announces Priority Review Acceptance for Ruxolitinib Phosphate Cream in China for Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=1102276998","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102276998?lang=en_us&edition=fundamental","pubTime":"2026-02-24 18:27","pubTimestamp":1771928860,"startTime":"0","endTime":"0","summary":"China Medical System Holdings Limited (CMS) reported that its subsidiary Dermavon Holdings Limited (Dermavon) received acceptance from the National Medical Products Administration (NMPA) on 24...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"gpt_icon":0},{"id":"2613794373","title":"China Medical System Holdings Limited Nda for Additional Indication Ad for Ruxolitinib Cream Accepted and Granted Priority Review in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2613794373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613794373?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:53","pubTimestamp":1771926828,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUE3RDXWN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BYV24P56.USD","IE00BMCWC346.EUR","LU2488822045.USD","IE00BVYPNQ40.USD","SG9999004220.SGD","BK1593","SG9999015986.USD","IE00BGHQDM52.EUR","SG9999015978.USD","SG9999015945.SGD","00867","SG9999015952.SGD","IE00BVYPNP33.GBP","BK1191"],"gpt_icon":0},{"id":"1104875656","title":"CMS Receives NMPA Acceptance and Priority Review for Ruxolitinib Cream's Atopic Dermatitis Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1104875656","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104875656?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:52","pubTimestamp":1771926741,"startTime":"0","endTime":"0","summary":"CMS announced that its subsidiary, Demai Pharmaceutical, a specialist in dermatological health currently pursuing an independent listing on the Main Board of the Hong Kong Stock Exchange, has...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","IE00BYV24P56.USD","IE00BMCWC346.EUR","BK1574","SG9999015986.USD","159992","SG9999015978.USD","AD","BK1191","BK4132","IE00BGHQDM52.EUR","BK1161","BK1593","SG9999015945.SGD","LU2488822045.USD","IE00BVYPNQ40.USD","00867","SG9999004220.SGD","SG9999015952.SGD","IE00BVYPNP33.GBP"],"gpt_icon":0},{"id":"2613791083","title":"China Medical System  -  Gets Acceptance From China's Nmpa for New Drug Application of Ruxolitinib Phosphate Cream for Treatment of Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2613791083","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613791083?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:49","pubTimestamp":1771926544,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK0N5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999015952.SGD","IE00BYV24P56.USD","SG9999015978.USD","BK1593","LU2488822045.USD","SG9999004220.SGD","IE00BMCWC346.EUR","SG9999015945.SGD","IE00BVYPNQ40.USD","BK1191","00867","SG9999015986.USD","IE00BVYPNP33.GBP","IE00BGHQDM52.EUR"],"gpt_icon":0},{"id":"2613791089","title":"China Medical System unit Dermavon wins China priority review for ruxolitinib cream in atopic dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2613791089","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613791089?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:48","pubTimestamp":1771926492,"startTime":"0","endTime":"0","summary":"China Medical System Holdings said its subsidiary Dermavon Holdings received acceptance from China’s NMPA for a new drug application seeking an additional indication for ruxolitinib phosphate cream to treat mild to moderate atopic dermatitis, and the filing was granted priority review by the CDE. Dermavon holds an exclusive license from Incyte to develop, register and commercialize the product in Mainland China, Hong Kong, Macau, Taiwan and 11 Southeast Asian countries, with a non-exclusive manufacturing license in the same territory.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Ho","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL4fHG48:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1593","SG9999015978.USD","LU2488822045.USD","IE00BVYPNP33.GBP","SG9999015952.SGD","BK4585","INCY","SG9999015986.USD","IE00BYV24P56.USD","BK4550","IE00BMCWC346.EUR","IE00BVYPNQ40.USD","BK4532","SG9999004220.SGD","SG9999015945.SGD","BK1191","00867","BK4139","IE00BGHQDM52.EUR"],"gpt_icon":0},{"id":"2613275621","title":"Assessing China Medical System Holdings (SEHK:867) Valuation After New Lidoderm Rights And AI Drug Discovery Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2613275621","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613275621?lang=en_us&edition=fundamental","pubTime":"2026-02-24 05:15","pubTimestamp":1771881333,"startTime":"0","endTime":"0","summary":"China Medical System Holdings (SEHK:867) has drawn fresh attention after securing exclusive mainland China distribution rights for Lidoderm lidocaine cataplasms and forming an AI-focused drug discovery partnership with Insilico Medicine across multiple R&D programs.\nSee our latest analysis for China Medical System Holdings.\nThe stock’s recent momentum has been firm, with a 12.45% 1 month share price return and 17.77% year to date share price return. The 1 year total shareholder return of...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/assessing-china-medical-system-holdings-sehk867-valuation-af-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/assessing-china-medical-system-holdings-sehk867-valuation-af-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4023","SG9999015978.USD","BK4585","IE00BGHQDM52.EUR","SG9999004220.SGD","BK4543","AIYY","BK4588","AI","BK1593","IE00BVYPNP33.GBP","BK1191","IE00BMCWC346.EUR","BK4551","BK4528","DCF","IE00BVYPNQ40.USD","SG9999015945.SGD","00867","SG9999015952.SGD","IE00BYV24P56.USD","SG9999015986.USD","BK4587","LU2488822045.USD"],"gpt_icon":0},{"id":"2612467291","title":"AI Drug Discovery Push And New Kidney Drug Trial Could Be A Game Changer For China Medical System Holdings (SEHK:867)","url":"https://stock-news.laohu8.com/highlight/detail?id=2612467291","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612467291?lang=en_us&edition=fundamental","pubTime":"2026-02-18 04:16","pubTimestamp":1771359400,"startTime":"0","endTime":"0","summary":"In early February 2026, Insilico Medicine announced a partnership with China Medical System Holdings to apply its AI platform to at least two co-developed drug discovery programs, while CMS separately received Chinese regulatory approval to begin human clinical trials of its self-developed complement factor B inhibitor CMS-D017 for complement-mediated kidney diseases.\nTogether, the AI-enabled collaboration and first-in-human trial clearance highlight CMS’s push to build an innovative...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/ai-drug-discovery-push-and-new-kidney-drug-trial-could-be-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/ai-drug-discovery-push-and-new-kidney-drug-trial-could-be-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00BYV24P56.USD","BK4543","IE00BGHQDM52.EUR","SG9999015952.SGD","BK4585","BK1191","BK1593","BK4023","BK4587","BK4551","IE00BMCWC346.EUR","IE00BVYPNQ40.USD","SG9999015945.SGD","SG9999015978.USD","SG9999015986.USD","LU2488822045.USD","BK4528","SG9999004220.SGD","IE00BVYPNP33.GBP","AI","00867","BK4588"],"gpt_icon":0},{"id":"2611483650","title":"Assessing China Medical System Holdings (SEHK:867) Valuation After New Kidney Trial Approval And AI Drug Discovery Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2611483650","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611483650?lang=en_us&edition=fundamental","pubTime":"2026-02-16 20:14","pubTimestamp":1771244062,"startTime":"0","endTime":"0","summary":"China Medical System Holdings (SEHK:867) has drawn fresh attention after Chinese regulators cleared human trials for its CMS-D017 kidney disease therapy, alongside a new AI-focused drug discovery partnership with Insilico Medicine.\nSee our latest analysis for China Medical System Holdings.\nThe recent CMS D017 trial clearance and AI drug discovery tie up come as China Medical System Holdings’ share price sits at HK$15.33, with a 30 day share price return of 9.34% and a 1 year total shareholder...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/assessing-china-medical-system-holdings-sehk867-valuation-af-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/assessing-china-medical-system-holdings-sehk867-valuation-af-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2488822045.USD","SG9999015986.USD","SG9999015952.SGD","00867","DCF","IE00BYV24P56.USD","IE00BVYPNQ40.USD","BK1191","SG9999004220.SGD","SG9999015945.SGD","SG9999015978.USD","IE00BMCWC346.EUR","BK1593","IE00BVYPNP33.GBP","IE00BGHQDM52.EUR"],"gpt_icon":0},{"id":"2611697251","title":"China Medical System Expands AI Drug Pipeline As Valuation Gap Persists","url":"https://stock-news.laohu8.com/highlight/detail?id=2611697251","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611697251?lang=en_us&edition=fundamental","pubTime":"2026-02-13 22:32","pubTimestamp":1770993144,"startTime":"0","endTime":"0","summary":"China Medical System Holdings (SEHK:867) has partnered with Insilico Medicine to co-develop AI supported drug discovery programs in central nervous system and autoimmune diseases.\nThe company also received clinical trial approval for its selective complement factor B inhibitor CMS-D017 in kidney disease and paroxysmal nocturnal hemoglobinuria.\n\nChina Medical System Holdings, trading at HK$15.13, has seen its share price gain 7.8% over the past month and 15.4% year to date, with a 1 year...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/china-medical-system-expands-ai-drug-pipeline-as-valuation-g","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/china-medical-system-expands-ai-drug-pipeline-as-valuation-g","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SG9999015945.SGD","BK4551","IE00BVYPNP33.GBP","BK4543","IE00BMCWC346.EUR","IE00BYV24P56.USD","BK4585","BK4023","AI","SG9999015952.SGD","SG9999015986.USD","IE00BGHQDM52.EUR","SG9999015978.USD","00867","BK4587","IE00BVYPNQ40.USD","BK1191","LU2488822045.USD","BK4528","BK1593","BK4588","SG9999004220.SGD"],"gpt_icon":0},{"id":"1199235412","title":"China Medical System Holdings Limited Announces Exclusive Distribution Agreement for Lidoderm® Lidocaine Cataplasms","url":"https://stock-news.laohu8.com/highlight/detail?id=1199235412","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199235412?lang=en_us&edition=fundamental","pubTime":"2026-02-12 18:12","pubTimestamp":1770891141,"startTime":"0","endTime":"0","summary":"On 12 February 2026, China Medical System Holdings Limited (the “Group”) signed an exclusive distribution agreement with Teikoku Pharma USA, Inc. (a subsidiary of Japan-based Teikoku Seiyaku Co.,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"gpt_icon":0},{"id":"1124626386","title":"CMS Secures Exclusive Distribution Rights for Lidoderm® Lidocaine Gel Patch","url":"https://stock-news.laohu8.com/highlight/detail?id=1124626386","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124626386?lang=en_us&edition=fundamental","pubTime":"2026-02-12 18:07","pubTimestamp":1770890873,"startTime":"0","endTime":"0","summary":"CMS announced that on February 12, 2026, the group, through its subsidiary, entered into an exclusive distribution agreement with Teikoku Pharma USA, Inc., a subsidiary of Japan's Teikoku Seiyaku...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BMCWC346.EUR","SG9999015986.USD","IE00BVYPNP33.GBP","SG9999015978.USD","BK1593","LU2488822045.USD","00867","IE00BVYPNQ40.USD","SG9999015945.SGD","SG9999015952.SGD","BK1191","IE00BGHQDM52.EUR","IE00BYV24P56.USD","SG9999004220.SGD"],"gpt_icon":0},{"id":"2610949707","title":"China Medical System Signs Exclusive Distribution Agreement for Lidoderm Lidocaine Cataplasms","url":"https://stock-news.laohu8.com/highlight/detail?id=2610949707","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610949707?lang=en_us&edition=fundamental","pubTime":"2026-02-12 17:55","pubTimestamp":1770890129,"startTime":"0","endTime":"0","summary":"China Medical System Holdings Limited announced that its subsidiaries have entered into an exclusive distribution agreement for the original drug Lidoderm Lidocaine Cataplasms. According to the company, the addition of this product is expected to support the development of the out-of-hospital market and have a positive impact on the Group’s operating performance. The transaction does not constitute a connected or notifiable transaction under the Hong Kong Listing Rules. The announcement was made on a voluntary basis to inform investors and shareholders of recent business developments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief via IIS","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL7j6gp9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","IE00BYV24P56.USD","SG9999004220.SGD","SG9999015986.USD","IE00BGHQDM52.EUR","BK1191","IE00BVYPNQ40.USD","LU2488822045.USD","SG9999015952.SGD","SG9999015978.USD","00867","SG9999015945.SGD","IE00BVYPNP33.GBP","IE00BMCWC346.EUR"],"gpt_icon":0},{"id":"2610949750","title":"China Medical System Holdings - Signing of Exclusive Distribution Agreement for Lidoderm Lidocaine Cataplasms","url":"https://stock-news.laohu8.com/highlight/detail?id=2610949750","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610949750?lang=en_us&edition=fundamental","pubTime":"2026-02-12 17:54","pubTimestamp":1770890070,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nFWN3Z80SF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1593","SG9999004220.SGD","00867","IE00BVYPNP33.GBP","IE00BMCWC346.EUR","IE00BYV24P56.USD","LU2488822045.USD","IE00BVYPNQ40.USD","SG9999015986.USD","SG9999015978.USD","IE00BGHQDM52.EUR","SG9999015952.SGD","SG9999015945.SGD","BK1191"],"gpt_icon":0},{"id":"1181439097","title":"Small Nucleic Acids Reshape Weight Loss Paradigm with INHBE and ALK7 Targets Showing Initial Validation","url":"https://stock-news.laohu8.com/highlight/detail?id=1181439097","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181439097?lang=en_us&edition=fundamental","pubTime":"2026-02-12 14:52","pubTimestamp":1770879137,"startTime":"0","endTime":"0","summary":"According to a research report, small nucleic acid drugs and GLP-1 based therapies demonstrate synergistic effects, with major weight loss companies already deploying small nucleic acid drug...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0276","SG9999015986.USD","SG9999015952.SGD","HK0000165453.HKD","00867","IE00BGHQDM52.EUR","IE00BMCWC346.EUR","BK1191","IE00BYV24P56.USD","LU2488822045.USD","BK1515","601456","BK1593","IE00BVYPNP33.GBP","LU1023057109.AUD","LU2543165471.USD","01177","LU0359201612.USD","IE00BZ08YS42.EUR","LU0359202008.SGD","SG9999004220.SGD","SG9999015945.SGD","IE00BZ08YR35.GBP","BK1147","01276","BK1564","BK1521","01456","BK1589","161027","IE00BZ08YT58.USD","LU0359201885.HKD","SG9999015978.USD","IE00BVYPNQ40.USD"],"gpt_icon":0},{"id":"2610696513","title":"BUZZ-InSilico hits fresh high on partnership deal with China Medical","url":"https://stock-news.laohu8.com/highlight/detail?id=2610696513","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610696513?lang=en_us&edition=fundamental","pubTime":"2026-02-10 10:17","pubTimestamp":1770689824,"startTime":"0","endTime":"0","summary":"BUZZ-InSilico hits fresh high on partnership deal with China Medical.** Shares of InSilico Medicine Cayman TopCo 3696.HK jump 9.9% to HK$73.8, a fresh high since their debut on December 30, 2025** Stock on track for biggest daily gain since February 3; on track for second session of rise** InSilico says it has entered into a strategic partnership with China Medical System 0867.HK on innovative drug development in the fields of central nervous system and autoimmune diseases** Insilico says the two parties will jointly advance the co-development of no fewer than two R&D programs** The company is expected to receive R&D funding support of up to several tens of millions of Hong Kong dollars for each program** Shares of China Medical System slip 2% ** Insilico stock has soared 202% from the HK$24.05 IPO price in nearly 6 weeks** YTD, Insilico shares up 92.5%, Hang Seng Biotech Index .HSBIO up 11.3%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nL1N3Z601U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BYV24P56.USD","SG9999015945.SGD","SG9999015952.SGD","IE00BMCWC346.EUR","SG9999004220.SGD","BK1191","BK1141","03696","IE00BGHQDM52.EUR","BK1593","IE00BVYPNQ40.USD","SG9999015978.USD","IE00BVYPNP33.GBP","00867","SG9999015986.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2610693787","title":"Insilico Medicine Enters Drug Development Partnership With China Medical System","url":"https://stock-news.laohu8.com/highlight/detail?id=2610693787","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610693787?lang=en_us&edition=fundamental","pubTime":"2026-02-10 09:38","pubTimestamp":1770687485,"startTime":"0","endTime":"0","summary":"Insilico Medicine  said it entered a drug development partnership with China Medical System , according to a Hong Kong bourse filing Tuesday.Under the agreement, the two sides will collaborate to co-develop at least two drugs.Insilico Medicine is expected to receive R&D funding support of up to \"several tens of millions of HKD\" for each program.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["03696","8A8.SI","IE00BVYPNP33.GBP","SG9999015978.USD","SG9999015986.USD","IE00BMCWC346.EUR","00867","IE00BGHQDM52.EUR","LU2488822045.USD","BK1191","SG9999004220.SGD","BK6079","BK1593","BK1141","IE00BYV24P56.USD","IE00BVYPNQ40.USD","SG9999015945.SGD","SG9999015952.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cms.net.cn","stockEarnings":[{"period":"1week","weight":-0.0357},{"period":"1month","weight":0.0473},{"period":"3month","weight":0.0977},{"period":"6month","weight":0.1162},{"period":"1year","weight":0.7965},{"period":"ytd","weight":0.1318}],"compareEarnings":[{"period":"1week","weight":0.0082},{"period":"1month","weight":-0.043},{"period":"3month","weight":0.0298},{"period":"6month","weight":0.0619},{"period":"1year","weight":0.1228},{"period":"ytd","weight":0.039}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"China Medical System Holdings Ltd is an investment holding company principally engaged in the production of medicines, as well as marketing, promotion and sales of drugs. The Company's products include Plendil, Ursofalk, Augentropfen Stulln Mono Eye Drops, Hirudoid, Atopic Piel Series and Vmonalisa, among others. Its major marketed products cover the cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetic fields. The Company distributes its products within domestic market and to overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.010984},{"month":2,"riseRate":0.6,"avgChangeRate":0.034663},{"month":3,"riseRate":0.466667,"avgChangeRate":-0.002353},{"month":4,"riseRate":0.533333,"avgChangeRate":0.029521},{"month":5,"riseRate":0.466667,"avgChangeRate":0.01146},{"month":6,"riseRate":0.666667,"avgChangeRate":0.005887},{"month":7,"riseRate":0.533333,"avgChangeRate":-0.008683},{"month":8,"riseRate":0.4,"avgChangeRate":0.021846},{"month":9,"riseRate":0.466667,"avgChangeRate":0.00566},{"month":10,"riseRate":0.5,"avgChangeRate":0.008421},{"month":11,"riseRate":0.5625,"avgChangeRate":0.054281},{"month":12,"riseRate":0.5625,"avgChangeRate":0.03433}],"exchange":"SEHK","name":"CMS","nameEN":"CMS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CMS(00867),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CMS(00867) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CMS,00867,CMS股票,CMS股票老虎,CMS股票老虎国际,CMS行情,CMS股票行情,CMS股价,CMS股市,CMS股票价格,CMS股票交易,CMS股票购买,CMS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CMS(00867),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CMS(00867) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}